Last year, Nkarta was celebrating data which showed that its natural killer (NK) cell therapy for acute myeloid leukaemia (AML) was showing remarkable efficacy in hard-to-
Harnessing the power of natural killer (NK) cells to attack cancer is as-yet an unproven strategy in oncology – but one that is garnering increased interest as clinical trials start to gene
Shares in Nkarta more than doubled yesterday on the results of early-stage clinical that suggested it could be on to a winner with its natural kill (NK) cell therapy platform.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh